Medicines360 represents an innovative approach to the pharmaceutical industry, combining technical expertise and a commitment to expanding access to effective and important pharmaceutical products for women, regardless of socioeconomic status, insurance coverage, or geographical location. The proceeds from the health products developed by this nonprofit pharmaceutical company are reinvested into advocacy, education, and partnership development to expand healthcare access across the world.
In collaboration with Actavis, another pharmaceutical company, Medicines360 developed a hormonal IUD called Liletta, the fourth IUD to be introduced into the US market. In 2015, FDA approved its use for preventing pregnancy for up to three years. In contrast to the other IUDs on the US market (Mirena, Skyla, and Paragard), Liletta was specifically designed to be more affordable. Liletta is available at the commercial price as well as a price of $50 for public health clinics enrolled in the 340B Drug Pricing Program, which provides greater access for women across the country.
<<Learn more about our other Featured Organizations>>